Form 8-K Guardant Health, Inc. For: Feb 23

Go back to Form 8-K Guardant Health, Inc. For: Feb 23

Guardant Health (GH) PT Lowered to $130 at Stifel

February 24, 2022 6:57 AM EST

Stifel analyst Daniel Arias lowered the price target on Guardant Health (NASDAQ: GH) to $130.00 (from $160.00) while maintaining a Buy rating.

The analyst commented, "GH finished the year with a good beat and an initial 2022 outlook that includes solid clinical volume growth expectations... More

Guardant Health (GH) PT Lowered to $110 at Cowen

February 24, 2022 6:42 AM EST

Cowen analyst Max Masucci lowered the price target on Guardant Health (NASDAQ: GH) to $110.00 (from $170.00) while maintaining an Outperform rating.

The analyst commented, "With the ECLIPSE trial readout expected in mid-2022, GH is approaching another landmark event for the field of cancer... More